Toward personalized TGFβ inhibition for pancreatic cancer

Cancer can be conceptualized as arising from somatic mutations resulting in a single renegade cell escaping from the constraints of multicellularity. Thus, the era of precision medicine has led to intense focus on the cancer cell to target these mutations that result in oncogenic signaling and sustain malignancy. However, in pancreatic ductal adenocarcinoma ( PDAC ) there are only four abundantly common driver mutations ( KRAS , CDKN 2A , TP 53 , and SMAD 4 ), which are not currently actionable. Thus, precision therapy for PDAC must look beyond the cancer cell. In fact, PDAC is more than a collection of renegade cells, instead representing an extensive, supportive ecosystem, having developed over several years, and consisting of numerous interactions between the cancer cells, normal mesenchymal cells, immune cells, and the dense extracellular matrix. In this issue, Huang and colleagues demonstrate how elucidation of these complex relationships within the tumor microenvironment ( TME ) can be exploited for therapeutic intervention in PDAC . They identify in a subset of PDAC with mutations in TGF β signaling, that a paracrine signaling axis can be abrogated to modulate the TME and improve outcomes.